Canstar Resources Provides Exploration and Corporate Update

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
49
Canstar Resources Provides Exploration and Corporate Update

TORONTO, Aug. 22, 2018 (GLOBE NEWSWIRE) -- CANSTAR RESOURCES INC. (TSXV: ROX) (OTCQB:CSRNF) (“Canstar” or the “Company”) is pleased to provide a corporate update and announces its 2018 exploration programs in Newfoundland and Labrador, Canada.

Corporate Update As announced in the press releases of July 31, 2018 and August 14, 2018, Canstar has completed the acquisition of the Newfoundland polymetallic exploration assets of Adventus Zinc Corporation and the Daniel's Harbour zinc project from Altius Resources Inc (“the Transaction”).  In addition, the Company has completed a consolidation of its shares on a five-for-one basis whereby shareholders of the Company have received one post-consolidation common share of the Company for each five (5) pre-consolidation common shares of the Company (“the Consolidation”).  After giving effect to the Consolidation, there are 44,500,473 Canstar shares issued and outstanding.  Adventus owns 17,336,339 shares of the Company or approximately 39% of the issued and outstanding common shares.  Altius owns 3,669,024 common shares of Canstar, or approximately 8.2% of the issued and outstanding common shares.

As a result of completion of the Transaction, funds have been released from escrow in respect of the private placement of the Company's subscription receipts as described in Canstar’s press release of April 18, 2018. The Company now has working capital of $1.3 million.

With the appointment of Christos Doulis as President and CEO, the corporate team has been strengthened significantly. His expertise as an analyst and in corporate development and investment banking, enhances the highly experienced and technical board comprising of Dennis Peterson, Chairman of the Board and directors Dr. David Palmer (Probe Metals Inc.), Jack Hurley (CFO), Patrick Reid, and Sam Leung (Adventus Zinc).

“With the completion of the Transaction and the release of funds previously held in escrow related to Canstar’s most recent private placement, the Company is now well positioned to advance its flagship Buchans Mary-March project and to continue consolidating base metal assets in Newfoundland,” commented Canstar CEO Christos Doulis. “I am pleased to be working with the Altius technical team which has a proven track record of success in mineral discoveries and strong roots in Newfoundland.”  

Buchans Mary-March Project Field work at the Buchans Mary-March project is anticipated to commence in September 2018 with the goal of further refining and prioritizing drill targets generated from the 2017 heli-borne time-domain EM survey and compiled historic data.  The project has produced historical drill results highlighted by the 1999 Phelps Dodge Discovery Hole MM-294-7, which had intersected high grade massive sulphides over 9.23m with an average grade of 10.33% Zn, 1.62% Pb, 0.66% Cu, 118.1 g/t Ag and 4.11 g/t Au.

Initial work will consist of re-logging, compilation and digitization of historic core obtained by Phelps-Dodge’s exploration program in the early 2000s, as well as trenching and soil sampling, which shall support an anticipated 3,000 to 5,000 metre drill program commencing in the fourth quarter of 2018.

In August 2018, Canstar also optioned the 275 hectare Exploits property (adjacent to the Buchans Mary-March project) as part of the Company’s ongoing efforts to consolidate the historic Buchans mining camp. 

“We are excited to re-focus Canstar on the historic Buchans base metal camp, which historically produced 16.2 million tonnes grading 14.51% Zn, 7.56% Pb, 1.33% Cu, 126 g/t Ag and 1.37 g/t Au over more than five decades. With new exploration tools now available, an experienced technical support team to utilize them, and the capital to pursue a robust exploration program, I am confident Canstar is well positioned to unlock value at the Buchans Mary-March project,” stated Canstar CEO Christos Doulis.

Daniel’s Harbour Project Field work at the Daniel’s Harbour project is anticipated to commence in September 2018 with the goal of refining targets for drilling anticipated in 2019. Initial work will focus on the re-logging and digitization of historic drill holes in order to generate a better understanding of the underlying geology of the project and to prioritize drill targets.

“Canstar’s recently acquired dominant land position at Daniel’s Harbour, where 7 million tonnes grading 7.8% Zn were mined historically between 1976 and 1990, demonstrates the Company’s commitment to consolidating base metal assets in known historic mining camps in Newfoundland. I look forward to working with the Altius technical team in advancing Daniel’s Harbour to the drill ready stage in 2019,” Canstar CEO Christos Doulis stated.

Qualified Person Lawrence Winter, Ph.D., P.Geo., Vice-President of Exploration for Altius, a Qualified Person as defined by National Instrument 43-101 - Standards of Disclosure for Mineral Projects, is responsible for the scientific and technical data presented herein and has reviewed, prepared and approved this release.

About Canstar Resources Canstar Resources is a Canadian mineral exploration and development company, with the objective to discover and develop economic mineral deposits in North America. Currently, Canstar's focus is to advance its flagship Mary March project and other mineral exploration properties in Newfoundland and Labrador. Canstar is based in Toronto, Canada and is listed on the Toronto Venture Exchange and trades under the symbol: ROX-V and on the OTCQB Exchange under the symbol CSRNF.

For further information, please contact:

Christos Doulis, President & CEO Tel:  647-557-3442 Email:  cdoulis@canstarresources.com

Karen Willoughby, Director Corporate Communications, TF:  1-866-936-6766 Email:  kwilloughby@canstarresources.com www.canstarresources.com

Forward-looking Statement Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This News Release includes certain "forward-looking statements" which are not comprised of historical facts. Forward-looking statements include estimates and statements that describe the Company’s future plans, objectives or goals, including words to the effect that the Company or management expects a stated condition or result to occur. Forward-looking statements may be identified by such terms as “believes”, “anticipates”, “expects”, “estimates”, “may”, “could”, “would”, “will”, or “plan”. Since forward-looking statements are based on assumptions and address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although these statements are based on information currently available to the Company, the Company provides no assurance that actual results will meet management’s expectations. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. Forward looking information in this news release includes, but is not limited to, the Company’s objectives, goals or future plans, statements, exploration results, potential mineralization, the estimation of mineral resources, exploration and mine development plans, timing of the commencement of operations and estimates of market conditions. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to failure to identify mineral resources, failure to convert estimated mineral resources to reserves, the inability to complete a feasibility study which recommends a production decision, the preliminary nature of metallurgical test results, delays in obtaining or failures to obtain required governmental, environmental or other project approvals, political risks, inability to fulfill the duty to accommodate First Nations and other indigenous peoples, uncertainties relating to the availability and costs of financing needed in the future, changes in equity markets, inflation, changes in exchange rates, fluctuations in commodity prices, delays in the development of projects, capital and operating costs varying significantly from estimates and the other risks involved in the mineral exploration and development industry, and those risks set out in the Company’s public documents filed on SEDAR. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 87

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 399

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 448

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Segway Powersports Dominates Baja 1000 with Class 2 Sweep

Updated Category News Views 72

Catching the eye of any betting man, Segway Powersports has turned its maiden outing at the relentless SCORE Baja 1000 into a rousing victory. Their arrival on this unforgiving stage with a one-two in Class 2 isn't just a lucky roll—you don't chance upon podium sweeps in such gritty contests. Dissecting the Drive: Commitment and Coordination Unfolding across Baja's...

Continue Reading
Pollo AI Unveils York AI: Automating Social Growth

Updated Category News Views 0

York AI Debuts as the New Kid on the Block Amid the hustle and bustle of a tech-savvy Singapore, Pollo AI’s latest offering, York AI, sashays onto the scene with the promise of putting social media growth on cruise control. We're talking about a digital sidekick that seems to know your online persona better than you do. It’s tailored for everyone from the small-time...

Continue Reading
Ascletis' Preclinical Successes: Future of Obesity Treatment

Updated Category News Views 14

Pharma Giants Eyeing a New Potential Well, it seems the world of pharma is buzzing with Ascletis’ latest developments in the obesity treatment arena. They’ve just showcased some intriguing preclinical data at ObesityWeek® 2026. The standout? A cocktail of advancements that might just put a dent in the obesity epidemic if further studies pan out. ASC30_48: A Daily...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 412

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Fapon's MEDICA 2026 Bid: Game-Changer or Same Old?

Updated Category News Views 89

Fapon's Ambitious Pitch at MEDICA: A Real Deal? MEDICA 2026 sees Fapon stepping up, laden with flashy promises and hardened expertise. Set up in Düsseldorf, these folks are pushing their Local Manufacturing Solutions harder than a door-to-door vacuum seller. The main pitch? Bolstering local IVD production with their comprehensive tech transfer services. How many outfits...

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 284

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading
Akeso's Gumokimab Wins NMPA Approval for AS Treatment

Updated Category News Views 115

Gumokimab Approved: A New Dawn in AS Treatment Yeah, the biotech world shifts gears today as Akeso's gumokimab received the green light from China's National Medical Products Administration (NMPA). This approval for treating ankylosing spondylitis, or AS, isn't just another checkbox for Akeso; it's a game-changer in tackling this chronic inflammatory disease. Why should...

Continue Reading

Top 5 Most Recently Viewed Articles

O-I Glass Announces Participation in Citi’s 2025 Conference

Updated Category News Views 208

O-I Glass Participation in the 2025 Basic Materials Conference PERRYSBURG, Ohio — O-I Glass, Inc., known for its commitment to creating exceptional glass products, is set to participate in the upcoming Citi’s 2025 Basic Materials Conference. This significant event will take place on a Wednesday in December, and features notable presentations from O-I's leadership....

Continue Reading
Osmium Partners Proposes Strategic Plan for Articore Growth

Updated Category News Views 104

Osmium Partners Proposes a Four-Step Plan for Articore Osmium Partners has recently made headlines with their proposal for Articore, aiming to elevate shareholder value through a methodical four-step approach. This initiative is driven by Osmium's belief that Articore's current management strategy lacks direction and has resulted in missed opportunities for growth and...

Continue Reading
Amplify Energy Set to Shine at EnerCom Denver Conference 2025

Updated Category News Views 135

Amplify Energy’s Participation in EnerCom Denver Conference Amplify Energy Corp. is gearing up to participate in the renowned annual EnerCom Denver Conference in 2025. This event, known for bringing together leading experts and investors in the energy sector, offers Amplify a prime platform to showcase its strategic initiatives and growth potential. Focus on Investor...

Continue Reading
Safe Life Expands CPR Training and AED Services through Acquisition

Updated Category News Views 197

Safe Life Strengthens National Coverage for Life-Saving Training Safe Life has made a significant move by acquiring HeartCert, a company known for its specialization in automated external defibrillators (AEDs) and CPR training. This acquisition allows Safe Life to broaden its reach into the Midwest, enhancing its commitment to providing life-saving training and equipment...

Continue Reading
Express Scripts Challenges FTC's Drug Pricing Conclusions

Updated Category News Views 106

Express Scripts Files Lawsuit Against the FTC Express Scripts, a major player in the pharmacy benefit manager sector, has recently taken legal action against the U.S. Federal Trade Commission (FTC). This lawsuit stems from a report that criticizes the role of pharmacy benefit managers in the pricing of medications. Express Scripts contends that the report's conclusions...

Continue Reading